Core Viewpoint - TEN Holdings, Inc. will implement a 1-for-15 reverse stock split, effective December 1, 2025, with trading on a split-adjusted basis starting December 2, 2025 [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 44.8 million to about 3.0 million [3]. - The effective time for the reverse stock split is set for 4:30 p.m. Eastern Time on December 1, 2025 [2]. - No fractional shares will be issued; instead, holders will receive cash payments for any fractional shares [3][4]. Group 2: Company Information - TEN Holdings operates through its subsidiary, Ten Events, Inc., providing event planning, production, and broadcasting services [6]. - The company specializes in virtual, hybrid, and physical events, utilizing its proprietary Xyvid Pro Platform for service delivery [6].

Core Viewpoint - ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split to comply with Nasdaq listing requirements and aims to increase the market price of its common shares [1][11]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 12:01 a.m. Eastern Time on November 28, 2025, with shares trading on a split-adjusted basis from that date [2]. - The number of outstanding common shares will decrease from approximately 53,811,110 shares to about 2,152,444 shares [3]. - Proportional adjustments will be made to equity incentive plans, stock options, and outstanding warrants in accordance with the reverse stock split [4]. Group 2: Compliance with Nasdaq - ProMIS received a deficiency letter from Nasdaq on January 8, 2025, indicating that its common shares had not maintained the minimum required closing bid price of at least $1.00 [8]. - The company was granted an additional 180-day compliance period until December 29, 2025, to regain compliance with the Bid Price Rule [10]. - The reverse stock split is part of the company's strategy to cure the deficiency and meet Nasdaq's listing standards [11]. Group 3: Shareholder Information - No fractional shares will be issued; shareholders entitled to fractional shares will receive cash instead [5]. - Stockholders with shares held in book-entry form or through a bank or broker will see the effects of the reverse stock split reflected in their accounts without needing to take action [6]. Group 4: Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative disorders, including Alzheimer's disease [13]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify novel targets associated with misfolded proteins [13].

Financial Data and Key Metrics Changes - The company held its 2025 Annual General Meeting, where various proposals were presented for stockholder voting, including a reverse stock split and reincorporation [1][2][3] - The preliminary report indicated that all proposals, including the amendment to the equity incentive plan and the issuance of shares to Streeterville Capital, were approved by a majority of votes [12][13][14][15] Business Line Data and Key Metrics Changes - Specific financial data and performance metrics for individual business lines were not disclosed in the meeting [1][2][3] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [1][2][3] Company Strategy and Development Direction - The company proposed a reverse stock split to potentially enhance its stock price and market perception, with a range of 1-for-2 to a maximum of 1-for-10 [9][13] - The reincorporation from Delaware to Nevada was aimed at potentially benefiting from a more favorable regulatory environment [10][13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [1][2][3] Other Important Information - The meeting included the election of seven directors, with all nominated candidates successfully elected [12] - The company plans to increase the number of shares authorized for issuance under its equity incentive plan to 5 million [14] Summary of Q&A Session - No Q&A session was documented in the provided meeting records [1][2][3]

Financial Data and Key Metrics Changes - The stockholders approved the proposal to grant discretionary authority to the Board of Directors for a reverse stock split within a range of 1-for-2 to a maximum of 1-for-10, indicating a strategic move to potentially enhance share value [12][13][14] - The company successfully ratified the selection of M&K CPAs as the independent registered public accounting firm for the fiscal year ending December 31, 2025, ensuring compliance and transparency in financial reporting [15] Business Line Data and Key Metrics Changes - The amendment to the 2022 equity incentive plan to increase the number of shares authorized for issuance to 5 million was approved, which may impact employee compensation and retention strategies [14] Market Data and Key Metrics Changes - The approval of the issuance of shares to Streeterville Capital, LLC, in prepaid financing transactions that may collectively equal or exceed 20% of the issued and outstanding shares indicates a significant capital raise strategy [14] Company Strategy and Development Direction - The company is pursuing a reincorporation from Delaware to Nevada, which may provide more favorable business regulations and tax benefits [13] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting, focusing instead on the proposals and voting results Other Important Information - The meeting concluded with the election of seven directors, ensuring continuity in governance and strategic direction [12][13] Summary of Q&A Session - There were no recorded questions or answers during the meeting, as the focus was primarily on the proposals and voting outcomes

Financial Data and Key Metrics Changes - The company has a market cap of approximately $12 million, with stock trading around $0.25 to $0.30 per share, indicating a significant decline from previous levels [30][53]. - The company is estimating to collect at least $50 million net from Crown Medical's initiatives, which is a significant potential cash influx [15][46]. Business Line Data and Key Metrics Changes - Crown Medical Collections is actively pursuing approximately $150 million in uncollected COVID testing claims, with a focus on underpaid claims from insurance companies [9][10]. - The BE-Smart Esophageal Cancer Test is positioned as a leading diagnostic tool for esophageal cancer, with a potential market value of $7 billion to $14 billion if reimbursement rates are between $1,000 and $2,000 per test [20][21]. Market Data and Key Metrics Changes - The company has identified a growing market for its esophageal cancer test, with 7 million endoscopies performed annually in the U.S. for high-risk patients, suggesting a substantial opportunity for commercialization [19][20]. - The company has a strong database from Nebula Genomics, which is considered more valuable than its current market cap, indicating significant underlying asset value [25]. Company Strategy and Development Direction - The company is focusing on strategic initiatives that could recognize significant underlying value, including a potential reverse stock split and a crypto treasury strategy [5][35]. - The management is committed to maintaining Nasdaq compliance to facilitate potential deals that could enhance shareholder value [35][49]. Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in the past year but expresses optimism about upcoming cash flow from Crown Medical, which is expected to transform the company's financial position [27][55]. - The management believes that the stock price will improve significantly once cash flow from Crown Medical starts to materialize, and they are exploring various funding options to support operations until then [43][46]. Other Important Information - The company has undergone significant restructuring, including the sale of its Pharmaloz manufacturing facility and the shutdown of its Nebula Genomics laboratory, to streamline operations and reduce overhead [26]. - Management emphasizes the importance of shareholder voting on proxies to support strategic initiatives and ensure the company's future [4][35]. Q&A Session Summary Question: Can you clarify the potential major deals being worked on? - Management is exploring multiple deals, including a reverse crypto strategy and other strategic initiatives that could be accretive for shareholders [37]. Question: Is it possible that the stock price will go up or down after a reverse stock split? - Management indicates that a reverse stock split could lead to an increase in stock price, especially if the company maintains its underlying asset value [39]. Question: Does the crypto treasury strategy remain part of the company's vision? - Management confirms that the crypto treasury strategy is still on the table, but they are also pursuing other potentially accretive deals [42]. Question: How will the company pay employees and board going forward with limited cash? - Management states that they have multiple investors willing to support the company with various funding options, ensuring operational continuity [43]. Question: When will the company stop mentioning the possibility of collecting $25 million in accounts receivables? - Management believes that significant cash flow will start coming in soon, leading to a different financial situation for the company [55]. Question: Is it realistic to use a go-it-alone strategy for BE-Smart? - Management is considering partnerships for the BE-Smart test but aims to minimize expenses and leverage existing resources as cash flow improves [56][59].

Core Points - Mawson Infrastructure Group Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-20, effective November 20, 2025 [1][2][4] - The reverse stock split aims to increase the per share market price to comply with Nasdaq's minimum bid price requirement [4][9] - Stockholders will not see a change in their percentage ownership, except for minor adjustments due to rounding [5][6] Company Overview - Mawson is a technology company that provides digital infrastructure for artificial intelligence, high-performance computing, and digital assets [7] - The company focuses on utilizing carbon-free energy sources, including nuclear energy, to power its digital infrastructure [7]

Core Viewpoint - Hudson Pacific Properties, Inc. will implement a 1-for-7 reverse stock split effective December 1, 2025, aimed at adjusting its stock price and improving market perception [1][2][3]. Reverse Stock Split Details - The reverse stock split will convert every seven shares of common stock into one new share, with the new trading symbol remaining "HPP" [2][4]. - The company's board of directors has approved the reverse stock split, which will also involve amendments to the company's charter [3][4]. - Proportionate adjustments will be made to outstanding equity awards and incentive plans as a result of the reverse stock split [4]. Impact on Shareholders - The reverse stock split will affect all shareholders uniformly, maintaining their percentage interest in the company's equity, except for cash payments for fractional shares [5]. - No fractional shares will be issued; instead, shareholders will receive cash equivalent to the fraction of a share they would have received [5]. Adjustments to Warrants - All outstanding pre-funded warrants will be adjusted accordingly, with every seven shares purchasable under the warrants representing one share post-split [6]. - The exercise price for pre-funded warrants will be adjusted to $0.07 per share, reflecting the reverse stock split [6]. Administrative Details - Computershare Trust Company, N.A. will act as the transfer and exchange agent for the reverse stock split, with no action required from registered stockholders [7].

Core Viewpoint - The article discusses the likelihood of stock splits among major corporations, specifically focusing on Berkshire Hathaway and Booking Holdings, suggesting that despite high share prices, these companies are unlikely to split their stocks due to their leadership philosophies and business strategies [2][3]. Group 1: Berkshire Hathaway - Berkshire Hathaway's Class A shares are priced at $761,800, indicating a strong performance and a low likelihood of a stock split, as CEO Warren Buffett prefers to attract long-term investors rather than short-term traders [4][5]. - Buffett's philosophy emphasizes stability and long-term investment, making a Class A stock split unlikely in the foreseeable future [5]. - The company has a solid foundation with a diversified portfolio and strong leadership, including the next CEO, Greg Abel, who has been with the company for over two decades [7][8][9]. Group 2: Booking Holdings - Booking Holdings has a current share price of approximately $5,100 and has previously conducted a reverse stock split in 2003, which typically indicates financial struggles [10]. - CEO Glenn Fogel has expressed reluctance towards stock splits, indicating a preference for long-term investors, which suggests that a forward split is unlikely [11]. - The company reported a 13% year-over-year revenue increase to $9 billion in Q3, with net income rising 9% to $2.7 billion, showcasing strong financial performance [12][14]. - Booking Holdings benefits from network effects, a growing travel demand, and a robust stock buyback program, making it an attractive investment regardless of potential stock splits [13][14].

Core Points - BiomX Inc. announced a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025 [1][2][3] - The reverse stock split was approved by stockholders at the 2025 Annual Meeting on October 16, 2025, with the final ratio set by the Board of Directors on November 13, 2025 [2] - Following the reverse stock split, the number of outstanding shares will decrease from approximately 29,006,165 to about 1,526,640 [4] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies to target specific pathogenic bacteria [5] - The company utilizes its BOLT platform to customize phage compositions aimed at treating chronic diseases with significant unmet medical needs [5]

Core Viewpoint - BiomX Inc. announced a one-for-nineteen reverse stock split of its common stock, effective November 25, 2025, to enhance its stock price and maintain compliance with NYSE American listing requirements [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert nineteen current shares into one new share, affecting all stockholders uniformly without altering their percentage ownership interest [3][4]. - The number of outstanding shares will decrease from approximately 29,006,165 to about 1,526,640, with adjustments for fractional shares [4]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive an additional fraction to round up to the next whole share [4]. Group 2: Company Background - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies targeting harmful bacteria for chronic diseases with significant unmet needs [5]. - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [5].